Product Details
| Product Name:
SCH900776 |
CAS No.:
891494-63-6 |
| Purity:
99.6% |
Supply Ability:
10g |
| Release date:
2024/11/01 |
Product Introduction
Bioactivity
| 名稱 | SCH900776 |
| 描述 | SCH900776 (MK-8776) is an agent targeting cell cycle checkpoint kinase 1 (Chk1) with potential radiosensitization and chemosensitization activities. |
| 細(xì)胞實(shí)驗(yàn) | For cell growth assays, cells are seeded at low density (500-1000 cells) in 96-well plates and then incubated with drug for 24 h (8 wells per concentration). Following treatment, cells are washed and grown in fresh media for 5-7 days at 37°C. Prior to attaining confluence, cells are washed, lysed, and stained with Hoechst 33258. Fluorescence is read on a microplate spectrofluorometer. Results are expressed as mean and standard error for the concentration of drug that inhibited growth by 50%. |
| 激酶實(shí)驗(yàn) | The Millipore Kinase Profiler service is used to generate general selectivity data for SCH 900776 against a broad range of serine/threonine and tyrosine kinases. Assays are typically run at two concentrations of SCH 900776 (0.5 and 5 μM), at a fixed (10 μM) concentration of ATP. Data are provided as percent activity remaining, relative to uninhibited controls. |
| 體外活性 | Administering 4 mg/kg of SCH 900776 30 minutes after gemcitabine triggers the γ-H2AX biomarker, while a dose of 8 mg/kg of SCH 900776 boosts tumor pharmacodynamics and degradation response. Incremental increases to 16 mg/kg and 32 mg/kg of SCH 900776 further improve tumor response. Notably, within BALB/c mice, the dose of SCH 900776 correlates with strong biomarker activation, independent of gemcitabine's intensified hematologic toxicity. |
| 體內(nèi)活性 | After 24 hours of exposure to hydroxyurea, SCH 900776 induces a dose-dependent loss of DNA replication capacity. SCH 900776 enhances the response of γ-H2AX to hydroxyurea, 5-fluorouracil, and cytarabine. By combining with antimetabolites, SCH 900776 triggers the accumulation of γ-H2AX within 2 hours, indicating replication fork collapse and subsequent double-strand DNA breaks. Additionally, SCH 900776 inhibits the accumulation of Chk1 pS296 autophosphorylation in a dose-dependent manner. SCH 900776 is a weak inhibitor of Chk2 and CDK2, with IC50 values of 1.5 μM and 0.16 μM, respectively. SCH 900776 does not significantly inhibit human liver microsomal cytochrome P450 subtypes 1A2, 2C9, 2C19, 2D6, and 3A4. |
| 存儲(chǔ)條件 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| 溶解度 | DMSO : 100 mg/mL (265.78 mM)
|
| 關(guān)鍵字 | SCH-900776 | Inhibitor | SCH 900776 | SCH900776 | Checkpoint Kinase (Chk) | inhibit | MK8776 |
| 相關(guān)產(chǎn)品 | Ribociclib | Prexasertib | Ro-3306 | Palbociclib monohydrochloride | Baricitinib | CASIN | Palbociclib | GW 441756 | Sodium Oxamate | Abemaciclib | Dinaciclib | Abemaciclib methanesulfonate |
| 相關(guān)庫(kù) | 高選擇性抑制劑庫(kù) | 經(jīng)典已知活性庫(kù) | 激酶抑制劑庫(kù) | 抗癌臨床化合物庫(kù) | 藥物功能重定位化合物庫(kù) | 抑制劑庫(kù) | 抗衰老化合物庫(kù) | 已知活性化合物庫(kù) | 抗癌活性化合物庫(kù) | 抗癌藥物庫(kù) |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
-
CAS:41552-82-3
$30.00 / 5mg
-
-
CAS:891494-64-7
$45.00 / 1mg
Recommended supplier
| Product name |
Price |
|
Suppliers |
Update time |
|
|
$/ |
|
Anhui Ruihan Technology Co., Ltd
|
2023-08-21 |
United States